Rockwell Medical (NASDAQ:RMTI) Releases Earnings Results

Rockwell Medical (NASDAQ:RMTI) announced its quarterly earnings results on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.20, FiscalAI reports. Rockwell Medical had a negative net margin of 7.98% and a negative return on equity of 15.41%. The company had revenue of $17.78 million during the quarter, compared to the consensus estimate of $17.82 million.

Here are the key takeaways from Rockwell Medical’s conference call:

• Second-quarter net sales rose 11% year over year to $17.8 million, driven by new Western U.S. customers, higher purchasing from existing customers, and pricing actions. Management said it remains on track for 2026 sales guidance of $70 million to $75 million.
• Gross margin expanded to 18% from 16% a year ago, while gross profit increased 30% to $3.2 million. The company attributed the improvement to lower manufacturing costs, automation, higher volumes, and operational efficiencies, and reiterated its full-year gross-margin target of 18% to 22%.
• Rockwell generated approximately $2.1 million in operating cash flow during the quarter and ended June with $24.8 million in cash and available-for-sale investments. Management reiterated expectations for positive operating cash flow and adjusted EBITDA of $1 million to $2 million in 2026.
• Expansion in the Western U.S. is gaining traction, with incremental volume carrying margins above the company average and liquid products representing a larger share of the regional mix. New and renewed customer agreements, generally structured for about three years with pricing escalators, are also increasing revenue visibility.
• The company is evaluating a complementary renal-care medical device that could address a sizable market and potentially face limited U.S. competition. Development remains early-stage, with investment funded from the existing balance sheet and no additional capital raise currently planned.

Rockwell Medical Trading Up 4.1%

Shares of RMTI traded up $0.31 during mid-day trading on Thursday, reaching $7.82. 81,208 shares of the company were exchanged, compared to its average volume of 32,157. Rockwell Medical has a 52 week low of $4.89 and a 52 week high of $21.00. The company has a debt-to-equity ratio of 0.23, a quick ratio of 3.43 and a current ratio of 3.74. The stock has a market capitalization of $31.05 million, a PE ratio of -5.21 and a beta of 1.60. The business has a 50 day simple moving average of $6.46 and a two-hundred day simple moving average of $8.23.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on RMTI shares. Wall Street Zen upgraded Rockwell Medical to a “hold” rating in a research report on Saturday, July 25th. HC Wainwright reissued a “buy” rating and set a $20.00 target price (up from $2.00) on shares of Rockwell Medical in a report on Thursday, July 9th. Finally, Weiss Ratings upgraded shares of Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $20.00.

Institutional Trading of Rockwell Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of Rockwell Medical by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after purchasing an additional 41,668 shares during the period. Vanguard Group Inc. boosted its stake in shares of Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after purchasing an additional 148,737 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Rockwell Medical during the fourth quarter worth $84,000. Finally, XTX Topco Ltd increased its position in shares of Rockwell Medical by 286.5% during the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after buying an additional 46,029 shares during the period. Institutional investors and hedge funds own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.